Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study.

Adema AY, de Roij van Zuijdewijn CLM, Hoenderop JG, de Borst MH, Ter Wee PM, Heijboer AC, Vervloet MG; NIGRAM consortium,.

BMC Nephrol. 2018 Nov 15;19(1):327. doi: 10.1186/s12882-018-1114-z.

2.

A novel mutation in mitochondrial DNA in a patient with diabetes, deafness and proteinuria.

Adema AY, Janssen MC, van der Heijden JW.

Neth J Med. 2016 Dec;74(10):455-457.

3.

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).

Adema AY, de Jong MA, de Borst MH, Ter Wee PM, Vervloet MG; NIGRAM Consortium.

Nephron. 2016;134(4):215-220. Epub 2016 Jul 22.

4.

Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.

Adema AY, van Ittersum FJ, Hoenderop JG, de Borst MH, Nanayakkara PW, Ter Wee PM, Heijboer AC, Vervloet MG; NIGRAM consortium.

PLoS One. 2016 Jan 25;11(1):e0144121. doi: 10.1371/journal.pone.0144121. eCollection 2016.

5.

α-Klotho is unstable in human urine.

Adema AY, Vervloet MG, Blankenstein MA, Heijboer AC.

Kidney Int. 2015 Dec;88(6):1442-1444. doi: 10.1038/ki.2015.238. Epub 2015 Aug 5.

PMID:
26244922
6.

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.

Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G, Peters GJ.

Springerplus. 2014 Dec 13;3:732. doi: 10.1186/2193-1801-3-732. eCollection 2014.

7.

The role of klotho on vascular calcification and endothelial function in chronic kidney disease.

Vervloet MG, Adema AY, Larsson TE, Massy ZA.

Semin Nephrol. 2014 Nov;34(6):578-85. doi: 10.1016/j.semnephrol.2014.09.003. Review.

PMID:
25498377
8.

Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.

Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijtenbeek R, Wosikowski K, Peters GJ.

Curr Drug Targets. 2014;15(14):1312-21.

PMID:
25382189
9.

Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.

Adema AY, de Borst MH, Ter Wee PM, Vervloet MG; NIGRAM Consortium.

J Ren Nutr. 2014 May;24(3):143-50. doi: 10.1053/j.jrn.2013.09.001. Epub 2013 Nov 9. Review.

PMID:
24216259
10.

Central retinal vein occlusion as an uncommon complication of sarcoidosis.

Adema AY, ten Kate RW, Plaisier MB.

Neth J Med. 2013 Apr;71(3):134-6.

11.

Rapid generation of microRNA sponges for microRNA inhibition.

Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MK, Halsema N, Slezak-Prochazka I, Ding Y, Kroesen BJ, van den Berg A.

PLoS One. 2012;7(1):e29275. doi: 10.1371/journal.pone.0029275. Epub 2012 Jan 6.

12.

Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.

Hodzic J, Giovannetti E, Diosdado B, Adema AD, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1214-22. doi: 10.1080/15257770.2011.629271. Erratum in: Nucleosides Nucleotides Nucleic Acids. 2012;31(6):501. Calvo, Begona Diosdado [corrected to Diosdado, Begoňa].

PMID:
22132977
13.

Lipophilic prodrugs and formulations of conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.

Peters GJ, Adema AD, Bijnsdorp IV, Sandvold ML.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1168-80. doi: 10.1080/15257770.2011.607143. Review.

PMID:
22132972
14.

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.

Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F, Sandvold ML, Peters GJ.

Invest New Drugs. 2012 Oct;30(5):1908-16. doi: 10.1007/s10637-011-9756-8. Epub 2011 Oct 15.

15.

Ascites as the presenting symptom in a patient with Churg-Strauss syndrome.

Adema AY, Schilder AM, Schreuder TC, Grünberg K, Bultink IE, Mulder CJ.

J Gastrointestin Liver Dis. 2010 Jun;19(2):199-201.

16.

Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase.

Peters GJ, Hodzic J, Ortega B, Giovannetti E, Adema AD, Broekhuizen R, Kaspers GJ, Hubeek I.

Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):408-13. doi: 10.1080/15257771003730078.

PMID:
20544528
17.

Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.

Adema AD, Losekoot N, Smid K, Kathmann I, Myhren F, Sandvold ML, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):394-9. doi: 10.1080/15257771003741166.

PMID:
20544525
18.

Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.

Temmink OH, Bijnsdorp IV, Prins HJ, Losekoot N, Adema AD, Smid K, Honeywell RJ, Ylstra B, Eijk PP, Fukushima M, Peters GJ.

Mol Cancer Ther. 2010 Apr;9(4):1047-57. doi: 10.1158/1535-7163.MCT-09-0932. Epub 2010 Apr 6.

19.

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.

Invest New Drugs. 2011 Jun;29(3):456-66. doi: 10.1007/s10637-009-9377-7. Epub 2010 Jan 12.

20.

Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.

Adema AD, Laan AC, Myhren F, Fichtner I, Verheul HM, Sandvold ML, Peters GJ.

Int J Oncol. 2010 Jan;36(1):285-94.

PMID:
19956857
21.

Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.

Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ.

Curr Med Chem. 2009;16(35):4632-43. Review.

PMID:
19903145
22.
23.

Troxacitabine prodrugs for pancreatic cancer.

Adema AD, Radi M, Daft J, Narayanasamy J, Hoebe EK, Alexander LE, Chu CK, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2007;26(8-9):1073-7.

PMID:
18058539
24.
25.

In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.

Radi M, Adema AD, Daft JR, Cho JH, Hoebe EK, Alexander LE, Peters GJ, Chu CK.

J Med Chem. 2007 May 3;50(9):2249-53. Epub 2007 Apr 10.

PMID:
17419604
26.

Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.

Adema AD, Zuurbier L, Floor K, Hubeek I, Kaspers GJ, Albertoni F, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):981-6.

PMID:
17065050
27.

Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells.

de Bruin M, Peters GJ, Oerlemans R, Assaraf YG, Masterson AJ, Adema AD, Dijkmans BA, Pinedo HM, Jansen G.

Mol Pharmacol. 2004 Oct;66(4):1054-60. Epub 2004 Jul 21.

28.

Comparison of bleomycin and radiation in the G2 assay of chromatid breaks.

Adema AD, Cloos J, Verheijen RH, Braakhuis BJ, Bryant PE.

Int J Radiat Biol. 2003 Aug;79(8):655-61.

PMID:
14555348

Supplemental Content

Support Center